格隆汇12月30日丨蓝帆医疗(002382.SZ)公布，为进一步聚焦核心主业、增厚现金储备、盘活存量资 产、缩短管理半径，蓝帆医疗股份有限公司拟出售全资子公司武汉必凯尔救助用品有限公司（简称"武 汉必凯尔"或"交易标的"）全部股权以获取现金对价。本次拟交易对方为深交所主板上市公司武汉明德 生物科技股份有限公司（股票代码002932.SZ，简称"明德生物"）。根据《深圳证券交易所股票上市规 则》的相关规定，明德生物不是公司关联方，本次交易预计不构成关联交易、对公司不构成《上市公司 重大资产重组管理办法》规定的重大资产重组事项。 ...

科森科技公告称，近日收到上交所关于出售全资子公司科森医疗股权的监管工作函。科森医疗2024年、 2025年前三季度分别实现营收3.66亿元、3.54亿元，净利润4112.18万元、4724.14万元，而同期公司持续 亏损。交易所要求公司补充披露多项内容，包括亏损原因、交易对财务影响等。独立董事访谈相关人 员、查阅资料后，未发现交易存在关联关系及未披露利益安排。对于内部交易，经专项审计，2018 - 2025年9月30日科森医疗与公司及子公司交易具备必要性、定价合理且有商业实质。 ...

Core Viewpoint - The company plans to sell its wholly-owned subsidiary, Changsha Yushun Display Technology Co., Ltd., to Huanuo Xingkong Technology Co., Ltd. for a total consideration of approximately 112 million yuan, aiming to optimize its asset structure and enhance operational efficiency [1] Group 1 - The board of directors and the supervisory board of the company will hold meetings on June 16, 2025, to review the proposal for the sale of the subsidiary [1] - The transaction involves Huanuo Xingkong acquiring 100% of Changsha Yushun's equity through a cash payment, with a total payment of 140 million yuan to be made to the company and its subsidiary, Xinhui Kai Technology (Shenzhen) Co., Ltd. [1] - The company has already received the total payment of 140 million yuan from Huanuo Xingkong and Changsha Yushun as of the announcement date [1] Group 2 - Following the completion of the equity transfer, Changsha Yushun will no longer be included in the company's consolidated financial statements [1] - The transaction is part of the company's strategy to promote high-quality development and improve asset operation efficiency [1]

Transaction Overview - Zhejiang Dahua Technology Co., Ltd. has approved the sale of 32.7321% equity in its subsidiary Hangzhou Huacheng Network Technology Co., Ltd. for a price of 71.68329 million RMB, corresponding to an investment of 25.5 million RMB [1] - The buyer is Shanghai Zhicheng Enterprise Management Partnership (Limited Partnership), which has been changed to Shanghai Zhicheng Technology Co., Ltd. [1] Transaction Progress - The change of the buyer does not involve any adjustments to other transaction terms [1] - Shanghai Zhicheng Technology Co., Ltd. has a registered capital of 115.7 million RMB and is engaged in various technology and consulting services [1] - The financial data of the controlling shareholder shows total assets of approximately 809.1 million RMB and a net asset of approximately 80.9 million RMB [1] Company Impact - The company no longer holds equity in Huacheng Network, and it will not be included in the company's consolidated financial statements [1]

Core Viewpoint - The independent directors of Zhongyifeng Lopuskin Material Technology Co., Ltd. have approved the sale of equity in a controlling subsidiary, which aligns with the company's overall business strategy to focus on core operations and optimize business layout [1][2]. Group 1 - The meeting was convened and conducted in accordance with relevant laws and regulations, with all independent directors participating and voting by signature [1]. - The voting results showed unanimous support for the proposal, with 3 votes in favor and no votes against or abstentions [1]. - The independent directors believe that the pricing of the related transaction is fair and based on assessment results negotiated between the parties, ensuring no harm to the company or its shareholders, particularly minority shareholders [2]. Group 2 - The proposal regarding the sale of subsidiary equity and related transactions will be submitted for review at the 22nd meeting of the sixth board of directors [2].